)
)
Camurus Investor Relations Material
Latest events
Q3 2024
Camurus
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Camurus
Access all reports
Segment Data
Access more data
Revenue by
Products and services
Product sale
Sales of development-related goods and services
Licensing revenues and milestone payment
Expenses by
Financials
Camurus AB is a pharmaceutical company developing and commercializing medicines for severe and chronic conditions. Camurus AB's product portfolio includes PRADAXA, which is indicated for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; TYSABRI for multiple sclerosis (MS) and psoriatic arthritis; DIFICID for antibiotic-associated diarrhea (AAD); EURAX for ulcerative colitis; and ORAPAVAN for nephrotic syndrome. Camurus AB is based in Lund, Sweden.
Key slides for Camurus
Q2 2024
Camurus
Company Presentation
Camurus
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
CAMX
Country
🇸🇪 Sweden